Attenuation and Stability of CHIKV-NoLS, a Live-Attenuated Chikungunya Virus Vaccine Candidate

被引:11
|
作者
Abeyratne, Eranga [1 ]
Freitas, Joseph R. [1 ]
Zaid, Ali [1 ]
Mahalingam, Suresh [1 ]
Taylor, Adam [1 ]
机构
[1] Griffith Univ, Inst Glyc, Emerging Viruses & Inflammat Res Grp, Gold Coast, Qld 4222, Australia
基金
英国医学研究理事会;
关键词
alphavirus; chikungunya virus; live-attenuated; vaccine; preclinical; BURDEN; EPIDEMIOLOGY; INFECTION; DISEASE;
D O I
10.3390/vaccines7010002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Our previous investigation of the nucleolar localisation sequence (NoLS) of chikungunya virus (CHIKV) capsid protein demonstrated the role of capsid in CHIKV virulence. Mutating the NoLS of capsid in CHIKV led to the development of a unique live-attenuated CHIKV vaccine candidate, termed CHIKV-NoLS. CHIKV-NoLS-immunised mice developed long-term immunity from CHIKV infection after a single dose. To further evaluate CHIKV-NoLS attenuation and suitability as a vaccine, we examined the footpad of inoculated mice for underlying CHIKV-NoLS-induced immunopathology by histological and flow cytometric analysis. In comparison to CHIKV-WT-infected mice, CHIKV-NoLS-inoculated mice exhibited minimal inflammation and tissue damage. To examine the stability of attenuation, the plaque phenotype and replication kinetics of CHIKV-NoLS were determined following extended in vitro passage. The average plaque size of CHIKV-NoLS remained notably smaller than CHIKV-WT after extended passage and attenuated replication was maintained. To examine thermostability, CHIKV-NoLS was stored at 21 degrees C, 4 degrees C, -20 degrees C and -80 degrees C and infectious CHIKV-NoLS quantified up to 84 days. The infectious titre of CHIKV-NoLS remains stable after 56 days when stored at either -20 degrees C or -80 degrees C. Interestingly, unlike CHIKV-WT, the infectious titre of CHIKV-NoLS is not sensitive to freeze thaw cycles. These data further demonstrate preclinical safety and stability of CHIKV-NoLS.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Development of a live-attenuated chimeric vaccine against the emerging Usutu virus
    Wang, Zheng-Jian
    Zhang, Rong-Rong
    Wu, Mei
    Zhao, Hui
    Li, Xiao-Feng
    Ye, Qing
    Qin, Cheng-Feng
    VACCINE, 2024, 42 (06) : 1363 - 1371
  • [42] From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine
    Chen, Lin H.
    Fritzer, Andrea
    Hochreiter, Romana
    Dubischar, Katrin
    Meyer, Stephanie
    JOURNAL OF TRAVEL MEDICINE, 2024, 31 (07)
  • [43] Correction to: Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine
    Buerger, Vera
    Maurer, Gabriele
    Kosulin, Karin
    Hochreiter, Romana
    Larcher-Senn, Julian
    Dubischar, Katrin
    Eder-Lingelbach, Susanne
    JOURNAL OF TRAVEL MEDICINE, 2024, 31 (08)
  • [44] ATTENUATED STRAIN OF AKABANE VIRUS - CANDIDATE FOR LIVE VIRUS-VACCINE
    KUROGI, H
    INABA, Y
    TAKAHASHI, E
    SATO, K
    AKASHI, H
    SATODA, K
    OMORI, T
    NATIONAL INSTITUTE OF ANIMAL HEALTH QUARTERLY, 1979, 19 (1-2) : 12 - 22
  • [45] The future of plague vaccines: hopes raised by a surrogate, live-attenuated recombinant vaccine candidate
    Rosenzweig, Jason A.
    Chopra, Ashok K.
    EXPERT REVIEW OF VACCINES, 2012, 11 (06) : 659 - 661
  • [46] Phenotypic and genetic characterization of a next generation live-attenuated yellow fever vaccine candidate
    Esson, Raphael
    De Sousa, Emanuel Rodrigues
    Benair, Loic
    Devard, Nicolas
    Soulet, Damien
    Gillet, Audrey
    Bassard, Isabelle
    Falque, Stephanie
    Chareyre, Audrey
    Marmin, Morgane
    Girerd-Chambaz, Yves
    Logvinoff, Carine
    Sanchez, Martha Erika Navarro
    VACCINE, 2022, 40 (38) : 5641 - 5650
  • [47] A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
    Yang Liu
    Xianwen Zhang
    Jianying Liu
    Hongjie Xia
    Jing Zou
    Antonio E. Muruato
    Sivakumar Periasamy
    Chaitanya Kurhade
    Jessica A. Plante
    Nathen E. Bopp
    Birte Kalveram
    Alexander Bukreyev
    Ping Ren
    Tian Wang
    Vineet D. Menachery
    Kenneth S. Plante
    Xuping Xie
    Scott C. Weaver
    Pei-Yong Shi
    Nature Communications, 13
  • [48] A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
    Liu, Yang
    Zhang, Xianwen
    Liu, Jianying
    Xia, Hongjie
    Zou, Jing
    Muruato, Antonio E.
    Periasamy, Sivakumar
    Plante, Jessica A.
    Bopp, Nathen E.
    Kalveram, Birte
    Kurhade, Chaitanya
    Bukreyev, Alexander
    Ren, Ping
    Wang, Tian
    Menachery, Vineet D.
    Plante, Kenneth S.
    Xie, Xuping
    Weaver, Scott C.
    Shi, Pei-Yong
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [49] Development of a live-attenuated influenza B ΔNS1 intranasal vaccine candidate
    Wressnigg, Nina
    Voss, Daniel
    Wolff, Thorsten
    Romanova, Julia
    Ruthsatz, Tanja
    Mayerhofer, Ines
    Reiter, Manfred
    Nakowitsch, Sabine
    Humer, Johannes
    Morokutti, Alexander
    Muster, Thomas
    Egorov, Andrej
    Kittel, Christian
    VACCINE, 2009, 27 (21) : 2851 - 2857
  • [50] Live-attenuated bacteria as a cancer vaccine vector
    Toussaint, Bertrand
    Chauchet, Xavier
    Wang, Yan
    Polack, Benoit
    Le Gouellec, Audrey
    EXPERT REVIEW OF VACCINES, 2013, 12 (10) : 1139 - 1154